Source: Zacks Investment Research News Agency
1 month ago•
Stock Medium Importance
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.
Related Symbols 1
SNDX SNDX
Source: Zacks Investment Research
Visit Source
0 0 0
Comment
Comments
0
No comments yet
Be the first person to comment on this news item.